Darunavir/Ritonavir + Lamivudine Versus Darunavir/Ritonavir +Emtricitabine/Tenofovir in Naïve HIV-1 Infected Subjects (ANDES)
A Phase 4, Randomized, Open Label, Controlled Study of Boosted Darunavir and Lamivudine Versus Boosted Darunavir and Emtricitabine/Tenofovir or Lamivudine/Tenofovir in Naïve HIV-1 Infected Subjects
Sponsor: Fundación Huésped
Listed as NCT02770508, this PHASE4 trial focuses on HIV-1 Infection and remains completed. Sponsored by Fundación Huésped, it has been updated 9 times since 2015, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Status Flow
Change History
9 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE4
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE4
-
Oct 2021 — Jul 2024 [monthly]
Completed PHASE4
-
Jan 2021 — Oct 2021 [monthly]
Completed PHASE4
▶ Show 4 earlier versions
-
Sep 2018 — Jan 2021 [monthly]
Completed PHASE4
Status: Active Not Recruiting → Completed
-
Jun 2018 — Sep 2018 [monthly]
Active Not Recruiting PHASE4
-
Feb 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE4
Status: Recruiting → Active Not Recruiting
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE4
First recorded
Nov 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Fundación Huésped
- Ministry of Science and Technology,Argentine
- National AIDS and STD programme,Argentine
- Richmond Laboratories
For direct contact, visit the study record on ClinicalTrials.gov .